 |
Merck opens regional hub in DubaiMerck, a leading science and technology company, has inaugurated its scientific office in the United Arab Emirates. The opening ceremony took place in the presence of Dr Amin Hussein Al Amiri, Assistant Undersecretary for Public H More… |
 |
Merck's drug for multiple sclerosis wins UAE approvalUS pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clini More… |
|
Merck's drug for multiple sclerosis wins UAE approvalUS pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clini More… |
 |
Merck wins ‘Employer of the Year’ awardMerck, one of the largest pharmaceutical companies in the world, has scooped the ‘Employer of the Year’ award for the second consecutive year in the three countries across Middle East and Africa (MEA): UAE, Egypt, and Turkey. More… |
 |
Merck appoints new head of MEAMerck, one of the leading science and technology companies, has appointed Paolo Carli as head of Middle East, Africa & Turkey (MEA) region for its healthcare business. In his new role, Paolo will be responsible for leading the More… |
 |
Merck backs World MS Day with awareness eventsMerck, a leading science and technology company, joined the global multiple sclerosis (MS) community in recognition of World MS Day yesterday (May 31), to raise awareness of this devastating disease. With the slogan ‘Life with MS& More… |
 |
Merck, Pfizer collaborate with Dako to develop avelumabMerck and Pfizer have signed a collaboration agreement with Dako, an Agilent Technology company, for the development of a potential companion diagnostic test (CDx), as part of a global strategic alliance to jointly develop and commercialise av More… |
 |
Merck and Pfizer to present updates for avelumabMerck and Pfizer is set to present six six abstracts on studies evaluating the potential role of programmed death-ligand 1 (PD-L1) inhibition and the safety and efficacy of the investigational cancer immunotherapy avelumab at an upcoming event More… |
 |
Ebola vaccine proves fully effective in Guinea trialThe world is for the first time on the verge of being able to protect humans against Ebola, the World Health Organization (WHO) said on Friday, as data from a trial in Guinea showed a vaccine was 100 per cent effective. Initial re More… |
 |
Sitagliptin ‘does not increase cardiovascular risks’The results of trial evaluating cardiovascular outcomes (Tecos) show that sitagliptin does not increase the risk of cardiovascular events in a diverse group of patients with type 2 diabetes at high cardiovascular risk, said a top professor. More… |
